LW
LWB.F Mesoblast Limited
- Market cap
- EUR 1.51B
- P/E
- -
- P/B
- 3.07x
- ROE
- -10.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is LWB.F undervalued?
Graham numberThe Graham number of Mesoblast Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Mesoblast Limited fundamental analysis
No fundamental analysis for Mesoblast Limited yet.
Mesoblast Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Mesoblast Limited
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Ryoncil for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as we…
Full company profileMesoblast Limited financial statements
Mesoblast Limited annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 2.41M | 17.3M | 16.7M | 32.2M | 7.46M | 10.2M | 7.50M | 5.90M | 17.2M | 120M |
| Gross Profit | -9.65M | 11.8M | 1.36M | - | - | - | 7.50M | 5.90M | 12.1M | 104M |
| Operating Income | -90.0M | -74.9M | -80.2M | -74.9M | -109M | -80.6M | -69.3M | -56.2M | -62.4M | -51.3M |
| EBITDA | -87.0M | -61.5M | -84.9M | -69.0M | -79.4M | -70.3M | -58.6M | -65.1M | -80.1M | -37.0M |
| Net Income | -76.8M | -35.3M | -89.8M | -77.9M | -98.8M | -91.3M | -81.9M | -88.0M | -102M | -57.5M |
| EPS | -0.18 | -0.07 | -0.18 | -0.13 | -0.15 | -0.14 | -0.10 | -0.08 | -0.08 | -0.04 |
| Balance Sheet | ||||||||||
| Total Assets | 656M | 692M | 652M | 734M | 745M | 662M | 669M | 669M | 785M | 773M |
| Total Liabilities | 139M | 146M | 171M | 184M | 163M | 165M | 168M | 189M | 187M | 205M |
| Shareholders' Equity | 517M | 546M | 481M | 549M | 581M | 497M | 502M | 480M | 597M | 568M |
| Cash & Short-term Investments | 45.8M | 37.8M | 50.4M | 129M | 137M | 60.0M | 70.9M | 62.6M | 161M | 47.4M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -95.5M | -75.0M | -57.8M | -56.4M | -101M | -65.8M | -63.3M | -48.5M | -50.0M | - |
| Capital Expenditure | 311K | 201K | 279K | 2.10M | 1.65M | 157K | 264K | 331K | 730K | 898K |
| Free Cash Flow | -95.8M | -75.2M | -58.1M | -58.6M | -108M | -66.0M | -63.6M | -48.8M | -50.7M | -44.7M |
| Ratios | ||||||||||
| ROE | -14.9% | -6.5% | -18.7% | -14.2% | -17.0% | -18.4% | -16.3% | -18.3% | -17.1% | -10.1% |
| ROA | -11.7% | -5.1% | -13.8% | -10.6% | -13.3% | -13.8% | -12.2% | -13.1% | -13.0% | -7.4% |
| Net Profit Margin | -3,184.7% | -203.5% | -537.0% | -242.4% | -1,325.3% | -894.6% | -1,091.7% | -1,490.3% | -593.9% | -47.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Mesoblast Limited dividends
Mesoblast Limited has not paid dividends in the last 9 fiscal years.
Who owns Mesoblast Limited
- Insiders 36.72%
- Institutions 17.54%
- Public & others 45.74%
- Shares outstanding 1.30B
- Free float 832M
Mesoblast Limited company profile
- Company name
- Mesoblast Limited
- Ticker
- LWB.F
- ISIN
- AU000000MSB8
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 108
- Fiscal year end
- June
- Address
- 55 Collins Street, Melbourne, VIC, Australia, 3000
- Phone
- 61 3 9639 6036
- Website
- mesoblast.com
About Mesoblast Limited
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Ryoncil for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Mesoblast Limited management
10- Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director · born 1957
- Mr. James Michael O'Brien CPA, M.B.A.Chief Financial Officer · born 1966
- Mr. Paul Hughes BPHARMGlobal Head of Corporate Communications & Joint Company Secretary
- Mr. Anthony WhealHead of Human Resources
- Dr. Paul J. Simmons BSc, Ph.D.Scientific Advisor to the Chief Executive Officer · born 1959
- Ms. Geraldine Storton B.Sc., M.B.A., MMSHead of Regulatory Affairs & Quality Management
- Mr. Daniel Devine B.Sc., J.D., M.B.AHead of Special Projects
- Mr. Justin Horst B.S.Head of Manufacturing
- Dr. Fiona See Ph.D.Senior VP & Head of Translational Research
- Mr. Marcelo SantoroChief Commercial Officer